Oaktree Acquisition Corporation II

Oaktree Acquisition Corporation II ("the corporation") was a blank check company formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses, referred to as our initial business combination. In September 2020, Oaktree Acquisition Corp. II completed an IPO raising $250 million.

On December 7, 2021, Oaktree Acquisition Corp. II entered into a business combination agreement with Alvotech Holdings S.A. and Alvotech (previously known as Alvotech Lux Holdings) at an implied total enterprise value of approximately $2.25bn. Alvotech is a global biotech company focused solely on the development and manufacture of biosimilar medicines for patients worldwide. On June 15, 2022, the merger closed between Oaktree Acquisition Corp. II and Alvotech, and on June 16, 2022, the combined company began trading under NASDAQ:ALVO.

For more information on Alvotecth, please visit: https://investors.alvotech.com/

Press Release:
Alvotech, a Global Pureplay Biosimilars Company, to Debut on Nasdaq Under the Ticker ALVO on June 16